00:00It's Benzinga bringing Wall Street to Main Street.
00:02Kimberly-Clark is preparing concessions to address EU antitrust concerns
00:07over its $40 billion acquisition of Tylenol maker Kenvu, according to Reuters.
00:12The European Commission is expected to formally outline its concerns this week.
00:16Kimberly-Clark could offer remedies before the regulator's preliminary review ends,
00:21September 29th, or face a four-month investigation.
00:24The deal would add Kenvu brands including Listerine, Aveeno, and Neutrogena
00:28to Kimberly-Clark's portfolio.
00:30Australia approved the acquisition last week on the condition
00:33that Kimberly-Clark divests Kenvu's carefree and stayfree period care brands there.
00:39South Africa granted conditional approval last month.
00:42For all things money, visit Benzinga.com.
Comments